In a crafty move FDA may have found a way to dampen controversy over a $375000 raredisease drug

In a crafty move, FDA may have found a way to dampen controversy over a $375,000 rare-disease drug

The FDA approved a rare-disease drug from famiily-run Jacobus, following Catalyst's $375,000 version of the drug.

More From BioPortfolio on "In a crafty move, FDA may have found a way to dampen controversy over a $375,000 rare-disease drug"